Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 20% on Thursday . The stock traded as high as C$0.06 and last traded at C$0.06. 143,300 shares were traded during trading, an increase of 124% from the average session volume of 63,941 shares. The stock had previously closed at C$0.05.
Hemostemix Price Performance
The company has a market cap of C$6.10 million, a P/E ratio of -1.75 and a beta of 0.18. The company’s 50-day moving average is C$0.05 and its two-hundred day moving average is C$0.06.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Read More
- Five stocks we like better than Hemostemix
- How Technical Indicators Can Help You Find Oversold Stocks
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- 3 Tickers Leading a Meme Stock Revival
- Why Dell Can Continue Winning in AI and Beyond
- Buy P&G Now, Before It Sets A New All-Time High
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
